Treatment of Vaginal Yeast Infections

First-Line Treatment Options

• The Centers for Disease Control and Prevention recommends fluconazole 150 mg oral tablet as a single dose for uncomplicated vaginal yeast infections, achieving clinical cure rates of 80-90% 1, 2
• The Centers for Disease Control and Prevention suggests short-course topical formulations (1-3 days) are equally effective for uncomplicated cases, including clotrimazole 500 mg vaginal tablet, single application, miconazole 200 mg vaginal suppository for 3 days, terconazole 0.8% cream 5g intravaginally for 3 days, and tioconazole 6.5% ointment 5g intravaginally, single application 2
• Topical azole creams and suppositories are oil-based and may weaken latex condoms and diaphragms 2

Confirming the Diagnosis Before Treatment

• The Infectious Diseases Society of America recommends laboratory confirmation, including wet mount (saline or 10% KOH) showing yeasts or pseudohyphae, or positive culture, before treating vaginal yeast infections 1, 2
• The Centers for Disease Control and Prevention suggests vaginal pH must be normal (<4.5) for diagnosis 1, 2
• If wet mount is negative but symptoms persist, the Infectious Diseases Society of America recommends obtaining vaginal cultures 1

When to Use Longer Treatment Courses

• The Infectious Diseases Society of America recommends extended therapy for complicated vulvovaginal candidiasis, including severe symptoms, recurrent infections, non-albicans Candida species, and immunocompromised patients 1
• For pregnant women, the American College of Obstetricians and Gynecologists recommends only topical azole antifungals for 7 days 3

Special Populations and Resistant Cases

• The Infectious Diseases Society of America suggests boric acid 600 mg gelatin capsules intravaginally daily for 14 days or topical nystatin for C. glabrata infections 1
• The Infectious Diseases Society of America recommends a two-phase approach for recurrent vulvovaginal candidiasis, including induction phase with topical azole or oral fluconazole for 10-14 days, and maintenance phase with fluconazole 150 mg once weekly for at least 6 months 1

Partner Management

• The Centers for Disease Control and Prevention recommends against treating sexual partners, as vulvovaginal candidiasis is not sexually transmitted 2, 3
• The Centers for Disease Control and Prevention suggests exception for male partners with symptomatic balanitis, who may benefit from topical antifungal treatment 2, 3

Follow-Up

• The Centers for Disease Control and Prevention recommends patients return only if symptoms persist or recur within 2 months 2, 3
• Women using OTC preparations who have persistent symptoms or recurrence within 2 months must seek medical evaluation 2

Over-the-Counter Considerations

• The Centers for Disease Control and Prevention recommends advising self-treatment only for women previously diagnosed with VVC who have recurrence of identical symptoms 2, 4
• OTC preparations require 7-day treatment courses 4

Alternative Treatment for Yeast Vaginitis in Fluconazole-Allergic Patients

Recommended Topical Alternatives

• The Centers for Disease Control and Prevention (CDC) recommends using topical intravaginal azole antifungals as first-line alternatives for uncomplicated yeast vaginitis in fluconazole-allergic patients, with short-course regimens (1-3 days) being equally effective to oral therapy 5
• The CDC recommends the following intravaginal options for uncomplicated yeast vaginitis in fluconazole-allergic patients:

Efficacy Considerations

• Topical azole drugs achieve 80-90% clinical cure rates, matching the efficacy of oral fluconazole 5
• These formulations are more effective than nystatin 5, 6

Important Caveats

• Oil-based preparations, such as all intravaginal creams and suppositories, may weaken latex condoms and diaphragms 5

Special Populations

• For pregnant women, only topical azole antifungals should be used, with 7-day regimens being more effective than shorter courses 6

Follow-Up

• Patients should return only if symptoms persist or recur within 2 months 5, 6

CDC Guideline for Over‑the‑Counter Azole Treatment of Vaginal Candidiasis Itching

First‑Line OTC Azole Cream Regimens

• The CDC recommends using clotrimazole 1 % cream (5 g intravaginally daily for 7–14 days) or miconazole 2 % cream (5 g intravaginally daily for 7 days) as first‑line OTC options, both achieving 80–90 % clinical cure rates. 7
• Clotrimazole 2 % cream (5 g intravaginally daily for 3 days) is an alternative short‑course regimen endorsed by the CDC. 8
• Miconazole 4 % cream (5 g intravaginally daily for 3 days) is also listed as an effective short‑course option. 8

Efficacy of Short‑ versus Long‑Course Regimens

• For uncomplicated vulvovaginal candidiasis, 3‑day regimens are equally effective as 7–14‑day courses, providing comparable cure rates. 9

Diagnostic Confirmation Before Self‑Treatment

• OTC azole therapy should be used only after a prior healthcare‑provider diagnosis of vaginal candidiasis. Confirmation criteria include:
  
  • Typical clinical symptoms (vulvar itching, white discharge, vulvar/vaginal erythema). 9
  • Normal vaginal pH (≤ 4.5). 9
  • Microscopic evidence of yeasts or pseudohyphae on a 10 % KOH wet mount, or a positive culture. 10

Management of Persistent or Recurrent Symptoms

• Patients should seek medical re‑evaluation if symptoms persist after completing OTC treatment or recur within two months. 9
• Potential reasons for treatment failure include:
  
  • Misdiagnosis (less than 50 % of self‑diagnosed cases are true vulvovaginal candidiasis). 8
  • Infection with non‑albicans Candida species that may require alternative agents. 10
  • Complicated infection necessitating extended therapy. 10

Situations in Which OTC Treatment Is Not Recommended

• Medical evaluation is advised for any of the following:
  
  • Severe presentations (extensive vulvar erythema, edema, excoriation, or fissures). 10
  • Recurrent infections (≥ 4 episodes per year). 10
  • Pregnancy (requires a 7‑day topical azole regimen). 10
  • Underlying diabetes or immunocompromised status. 10

OTC Suppository Options (Equally Effective to Creams)

• OTC azole suppositories provide cure rates comparable to creams and are endorsed by the CDC. 9